The above considering, we could hypothesize that the effect of TRAIL signaling on MASLD may be dual-faceted, similar to that supported for TNF-α [38], i.e., TRAIL may initially target to alleviate MASLD, but, if this fails, TRAIL may contribute to the disease progression; however, this hypothesis needs verification. Here, TNFSF10 is linked to metabolic dysfunction-associated steatotic liver disease.